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Abstract Glutathione S-transferases and the cytochrome P450
system have been proposed for the vascular biotransformation
systems in the metabolic activation of organic nitrates. The
present study was designed to elucidate the role of human
cytochrome P450 isoforms on nitric oxide formation from
organic nitrates using lymphoblast microsomes transfected with
human CYP isoforms cDNA. CYP3A4-transfected microsomes
had the most effective potential of nitric oxide formation from
isosorbide dinitrate. Anti-CYP3A2 antibody (which cross-reacts
with CYP3A4) or ketoconazole (an inhibitor of the CYP3A
superfamily) inhibited nitric oxide formation from isosorbide
dinitrate in rat heart microsomes. Immunohistochemistry of
human heart also showed intense bindings of CYP3A4 antibody
in the endothelium of the endocardium and coronary vessels.
These results suggest that the CYP3A4-NADPH-cytochrome
P450 reductase system specifically participates in nitric oxide
formation from isosorbide dinitrate.
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1. Introduction
Organic nitrates such as glyceryl trinitrate (GTN) and iso-
sorbide dinitrate (ISDN) elicit vasodilatation by generating
nitric oxide (NO) which activates soluble guanylyl cyclase
and a cGMP-dependent e¡ector cascade that ¢nally leads to
relaxation of vascular smooth muscles [1^5]. The enzyme(s) in
vascular smooth muscle that mediate(s) the formation of NO
from organic nitrates has/have yet to be identi¢ed. Formation
of NO from GTN has been demonstrated in intact bovine
pulmonary [6] and coronary [7] arteries, cultured porcine
aortic smooth muscle cells [8] and in a broken cell preparation
from bovine coronary [9] and dog carotid [10] arteries. It was
demonstrated that in cell-free preparations from rat liver, cy-
tochrome P450 (P450)-dependent enzymes as well as gluta-
thione S-transferase (GST) may catalyze NO formation
from organic nitrates [11,12]. Furthermore, it has been re-
ported that NO formation from these compounds is mediated
by a P450 system rather than by GST or free thiols in cultured
RFL-6 cells [13]. These evidences were brought by the usage
of either inhibitor, SKF525A, an inhibitor for global P450, or
sulfobromophtalein (SBP), an inhibitor for GSTs. The unan-
swered questions are, however, which isoform(s) of P450 fam-
ilies is/are responsible for the P450-elicited organic nitrates-
derived tissue NO formation. The present study was per-
formed to demonstrate NO formation from organic nitrates
in the microsomes of lymphoblasts transfected with various
human CYP isoform cDNAs and which P450 isoforms exist
on the human heart.
2. Materials and methods
2.1. Chemicals
Glucose-6 phosphate (G6P), glucose-6 phosphate dehydrogenase
(G6PDH) and NADPH were purchased from Oriental Yeast (Tokyo,
Japan). Microsomes from human lymphoblasts transfected with
CYP1A2, 2A6, 2D6, 2C9, 2E1, 3A4 or 4A11 genes were obtained
from Gentest (Woburn, MA, USA). Other reagents used were of
analytical grade from Wako Pure Chemicals (Osaka, Japan). ISDN
was a gift from Eisai (Tokyo, Japan). ISDN (100 mM) was dissolved
in 100% methanol. Ketoconazole or SBP was used as an inhibitor for
the CYP3A family or GSTs, respectively.
2.2. ISDN-induced NO formation in transfected human CYP isoforms
A CYP-transfected microsome preparation (100 pmol) was sus-
pended in 0.5 ml (total volume) of phosphate-bu¡ered saline (PBS,
pH 7.4) and incubated with 3.3 mM G6P, 0.5 U/ml G6PDH, 1 mM
NADPH, 3.3 mM MgCl2W6H2O and 200 WM ISDN for 15 min at
37‡C. After incubation, samples were immediately kept on ice and
centrifuged at 100 000Ug for 60 min at 4‡C. Since NO released
from ISDN is immediately converted to nitrite under aerobic condi-
tions, supernatants were used for the analysis of nitrite (NO32 ) by
HPLC [14].
2.3. The e¡ect of anti-CYP3A2, 2E1 or 2C11 antibody on
ISDN-induced NO formation
Rat heart microsomes were prepared as described previously [15].
Polyclonal antibodies against P450 PB-1 (CYP3A2), CYP2E1 and
P450 UT-2 (CYP2C11) were raised in rabbits and immunoglobulin
G (IgG) fractions were prepared as reported previously [16,17]. Hu-
man CYP3A4 is a homologue of rat CYP3A2. We already reported
that an antibody against rat CYP3A2 cross-reacted with human
CYP3A4 and completely inhibited the catalytic activities of human
CYP3A4 [17]. 500 Wl of microsome (0.3 mg protein/ml) suspended in
PBS (pH 7.4) was pre-incubated with anti-CYP isoform antibody
(0.025^0.1 mg IgG) for 20 min at room temperature and subsequently
with 100 WM ISDN and cofactors (G6P, G6PDH, NADPH and
MgCl2) for 15 min at 37‡C. After incubation, samples were immedi-
ately kept on ice and centrifuged at 100 000Ug for 60 min at 4‡C.
Supernatants were also used for the analyses of nitrite by HPLC
[14].
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To certify CYP-induced NO release from ISDN, NO was directly
measured using an NO-selective electrode (model NO-501, Inter Med-
ical, Tokyo, Japan). Brie£y, 1 ml of microsomes (0.3 mg/ml) was pre-
incubated with or without anti-CYP3A2 (0.1 mg IgG) or ketocona-
zole (10 WM) as described above. Then, the NO electrode was care-
fully placed and monitored in the microsome suspension in the pres-
ence of cofactors (G6P, G6PDH and MgCl2). Then, ISDN (100 WM)
and NADPH (1 mM) were added successively to initiate the reaction.
The obtained electrical current was recorded as previously reported
[18] and a change in the electrical current was considered as an index
of NO release [19]. We checked the response of NO electrodes using
S-nitroso-N-acetyl-DL-penicillamine or a NO-saturated solution (1.9
mM of NO).
2.4. Immunohistochemistry of human heart vessels
Samples were obtained at the Okayama University Medical School
from autopsy cases without heart failure. Cut pieces of heart samples
were ¢xed with 10% bu¡ered formalin and embedded in para⁄n. The
4 Wm thin sections depara⁄nized with xylol and ethanol. They were
treated with 0.3% hydrogen peroxide in methanol for the inhibition of
endogenous peroxidase activity for 20 min and normal goat serum
(Dako, Kyoto; diluted to 1:100) for the inhibition of non-speci¢c
binding of the second antibody for 30 min. Polyclonal antibodies
for human CYP3A4, CYP2E1, CYP2C9, CYP1A1, CYP2A6 and
CYP2D6 (U300) for overnight treatment at 4‡C, biotin-labelled
goat anti-rabbit IgG serum (Dako; diluted to 1:200) including normal
serum (1:80) for 40 min and avidin-biotin-peroxidase complex (Vector
Laboratories, Burlingame, CA, USA; diluted to 1:100) for 40 min
were serially applied. The stain intensity by the bridged immunoper-
oxidase (peroxidase anti-peroxidase/diaminobenzidine) was checked
under microscopy. And then, methyl green or hematoxylin was ap-
plied for nuclear staining. Non-immune rabbit serum in place of spe-
ci¢c antibodies was used for the negative control. Anti-CYP isoforms
with an excess fresh microsomes were pre-incubated with each anti-
body for overnight at 4‡C. The absorbed antibody also showed neg-
ative staining.
2.5. Statistical analysis
Unless otherwise stated, data are presented as means þ S.E.M.
3. Results
3.1. ISDN-induced NO formation in transfected human CYP
isoforms
The microsomal preparations from transfected lympho-
blasts catalyzed NO formation, from ISDN as a substrate
(Fig. 1). CYP3A4-transfected microsomes had the most e¡ec-
tive potential of NO32 formation from ISDN. In contrast,
CYP1A2 and CYP4A11 had little catalytic activity to gener-
ate NO32 from ISDN. Microsome- or NADPH-free systems
did not generate NO32 from ISDN.
3.2. Inhibitory e¡ect of anti-CYP antibodies on ISDN-induced
NO32 formation in rat heart microsomes
NO32 formation from ISDN was 4.84 þ 0.22 WM for 15 min
in rat heart microsomes. Neither the microsome-free nor
NADPH-free reaction mixture produced NO32 . Pretreatment
of rat heart microsomes with anti-CYP3A2 antibody inhibited
NO32 formation dose-dependently (Table 1) and anti-CYP2E1
or -CYP2C11 antibodies did not inhibit the NO32 formation.
Pretreatment with ketoconazole also inhibited NO32 formation
by about 65%. Pretreatment with SBP (100 WM) instead of
antibody did not inhibit the NO formation (data not
shown).
3.3. Inhibitory e¡ect of anti-CYP3A2 or ketaconazole on
ISDN-induced NO formation in rat heart microsomes
To gain direct evidence of NO release from ISDN, a NO
electrode was used. Typical tracing ¢gures are shown in Fig.
2. Addition of ISDN alone to the reaction media did not
generate NO. Addition of NADPH started to produce NO
formation. Pretreatment with anti-CYP3A2 antibody or keto-
conazole inhibited NO biotransformation from ISDN. Total
levels of NO for 15 min were shown in Table 1.
3.4. Immunohistochemistry of human heart
A list of human specimens from autopsy is shown in Table
2. Fig. 3 shows the typical immunohistochemistry of CYP3A4
in the endocardium of patient 1 (left) and the coronary artery
of patient 2 (right). Intense antibody binding of CYP3A4,
CYP2E1 and CYP1A2 was observed in the endothelium of
the endocardium and coronary vessels. No antibody binding
Fig. 1. ISDN-derived NO formation in human CYP isoforms-trans-
fected microsomes as catalysts. A CYP-transfected microsome (100
pmol) was suspended in 0.5 ml of PBS (pH 7.4) and incubated with
3.3 mM of G6P, 0.5 U/ml G6PDH, 1 mM NADPH, 3.3 mM
MgCl2W6H2O and 200 WM ISDN for 15 min at 37‡C. After incuba-
tion, samples were immediately kept on ice and centrifuged at
100 000Ug for 60 min at 4‡C. Supernatant was used for the analysis
of nitrite by HPLC. Data represent means of triplicate determina-
tions and S.E.M.
Table 1
The e¡ect of anti-CYP isoforms antibody or a CYP3A inhibitor on
NO formation from ISDN in rat heart microsomes
% Inhibition
NO32 NO
Control (WM) (4.84 þ 0.22) (5.37 þ 1.49)
anti-CYP3A2 (0.025 mg IgG) 18.3 þ 11.6 ^
(0.05 mg IgG) 44.0 þ 18.1 ^
(0.1 mg IgG) 51.9 þ 22.5 86.4 þ 28.0
anti-CYP2E1 (0.1 mg IgG) 0 0
anti-CYP2C11 (0.1 mg IgG) 0.1 þ 2.2 0
Ketoconazole (10 WM) 64.5 þ 0.8 75.6 þ 5.5
One ml microsomes (0.3 mg protein/ml) suspended in PBS (pH 7.4)
was pre-incubated with each anti-CYP isoform antibody (0.025^0.1
mg IgG) or ketoconazole (10 WM) for 20 min at room temperature
and then incubated with 100 WM of ISDN and cofactors as de-
scribed in Fig. 1. 15 min after incubation, samples were immediately
kept on ice and centrifuged at 100 000Ug for 60 min at 4‡C. Super-
natant was also used for the analysis of nitrite by HPLC. NO levels
for 15 min measured by a NO electrode were calculated [18]. Data
represent means of triplicate determinations and S.E.M.
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of CYP2C9 or CYP2D6 was observed. Smooth muscle cells
were slightly stained by all antibodies. Other specimens from
patient 3, 4 and 5 were the same as Fig. 3.
4. Discussion
We showed the participation of the CYP isoforms, espe-
cially of the CYP3A4-NADPH-cytochrome P450 reductase
system, in NO formation from an organic nitrate. We also
showed evidence of the localization of CYP isoforms in the
human endocardium and coronary vessels.
It has been demonstrated that both GST and P450 denitrate
various organic nitrates [7,12,13,20^23]. In fact, it has been
reported that the P450 system and NADPH-cytochrome P450
reductase system are present in vascular smooth muscle in
rabbit [24] and rat aortic microsomes possess P450 activity
[22]. However, the role of P450 isoforms on human vascular
site(s) of organic nitrate biotransformation has not been clari-
¢ed. In this study, we found that intense antibody bindings of
some CYP isoforms were observed in the endothelium of the
endocardium, coronary arteries and veins. This discrepancy
may be due to methodological di¡erences between the immu-
nohistochemistry and Western blotting of aortal microsomes
and positional and species di¡erences of vessels. Although
CYP3A4, CYP2E1 and CYP1A2 were present on the vascular
endothelium in human heart, CYP3A4 generated NO from
ISDN more than twice that generated by other isoforms. Con-
sistent with these results, ISDN-derived NO generation in rat
heart microsomes was strongly inhibited only by anti-
CYP3A2 antibody or ketoconazole (CYP3A subfamily inhib-
itor).
A preliminary experiment also revealed that each anti-
CYP3A2 antibody, but not SBP, also inhibited biotransfor-
mation of organic nitrate by the NADPH-dependent P450-
P450 reductase system in human hepatic microsomes. This
supports the former reports that NO formation from organic
nitrates is mediated by a P450 enzyme system rather than by
GSTs [7,13,25,26].
Development of tolerance to organic nitrate is a clinical
problem [27,28]. The cause is not known. Organic nitrate
therapy, GTN as an example, appears to be associated with
a depletion of free thiols in vascular smooth muscle [29]. It is
known that NO reacts with various molecules such as heme or
thiols [30]. Our previous report suggested that P450, which is
a heme protein, might be inactivated at the sites of the heme
moiety and cysteinyl residues by NO [31]. When CYP3A4
plays a major role in the NO release from organic nitrates
as this paper describes, generated NO may partially inhibit
the catalytic activity of this isoform (and others), which will
result in a decrease of NO generation from organic nitrates.
This may be related to development of tolerance of organic
nitrates. Consistent with our notions (formation of nitro-
sothiol(s) of P450), pronounced activation of a partially puri-
¢ed human soluble guanylate cyclase by GTN was observed
after the addition of cysteine [32]. This mechanism might be
due to reversed active sites of P450 cysteinyl residues by cys-
teine.
Fig. 2. Typical tracing of NO production from ISDN by CYP3A4-induced biotransformation. One ml of rat heart microsome (0.3 mg protein/
ml) suspended in PBS (pH 7.4) was pre-incubated in the absence or presence of anti-CYP3A2 antibody (0.1 mg IgG) or ketoconazole (10 WM)
for 20 min at room temperature and then incubated with 100 WM ISDN and cofactors as described in Fig. 1. A NO electrode was placed in
the mixture before ISDN addition. Then, NADPH (1 mM) was added to initiate the reaction.
Table 2
Human specimens
Autopsy diagnosis Age Sex
1. Lung cancer 20 Male
2. Sepsis 76 Male
3. Hepatocellular carcinoma 59 Female
4. Malignant lymphoma 44 Male
5. Renal cell carcinoma 45 Male
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In summary, we have provided strong and direct evidence
for CYP3A4-mediated biotransformation of organic nitrates
in human heart vessels.
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